Hana Biosciences Announces $14.7 Million Private Placement
19 Octobre 2005 - 9:41PM
Business Wire
Hana Biosciences Inc. (AMEX: HBX), a South San Francisco-based
biopharmaceutical company focused on advancing cancer care,
announced today that it has received commitments led by several
institutional investors to purchase approximately 3.7 million
shares of Hana's common stock at a price of $4.00 per share,
resulting in aggregate gross proceeds of approximately $14.7
million. The investors will also receive warrants to purchase an
additional 737,000 common shares. The transaction is subject to
certain customary closing conditions and is expected to close by
Oct. 21, 2005. Oppenheimer & Co. Inc. served as the lead
placement agent, with Griffin Securities acting as co-placement
agent. Current and new investors include ProMed Management, Lehman
Brothers, Pogue Capital Management, Perceptive Life Sciences Fund,
Atlas Equity, Mosaix Ventures, Coqui Capital and Panacea Asset
Management. The shares and warrants will be issued in a private
placement under Regulation D of the Securities Act of 1933, as
amended. The company has committed to prepare and file a
registration statement covering the resale of the common stock
purchased by these investors within 30 days of closing and will use
its best efforts to obtain effectiveness no later than 90 days
after closing. "Completing this financing with some of the
highest-quality investors in the biotechnology sector underscores
the significant potential of our clinical stage oncology pipeline,"
stated Mark Ahn, Ph.D., president and CEO of Hana Biosciences.
"This financing allows Hana to continue to aggressively move its
product candidates forward, and build value for both patients and
shareholders." Hana has three clinical stage products in
development: Talotrexin (PT-523), Zensana(TM) (ondansetron oral
spray), and IPdR. -- Talotrexin (PT-523) is in Phase I trial in
solid tumors, Phase I/II in NSCLC (non-small cell lung cancer), and
Phase I/II in ALL (acute lymphocytic leukemia). Phase II trials in
cervical, endometrial, and ovarian cancers are forthcoming. --
Zensana(TM) (ondansetron oral spray) is commencing pivotal clinical
trials in the fourth quarter of 2005 under a 505(b)(2)
registration, with a targeted NDA submission in 2006 and potential
U.S. launch in 2007. -- IPdR is initially being developed in a
Phase I clinical trial for the treatment of colorectal, gastric,
liver and pancreatic cancers. In addition, a Phase I/II clinical
trial in glioblastoma multiforme, a type of brain cancer, will
commence shortly. About Hana Biosciences Hana Biosciences Inc. is a
South San Francisco, Calif.-based biopharmaceutical company that
acquires, develops and commercializes innovative products to
advance cancer care. The company is committed to creating value by
building a world-class team, accelerating the development of lead
product candidates, expanding its pipeline by being the alliance
partner of choice, and nurturing a unique company culture.
Additional information on Hana Biosciences can be found at
www.hanabiosciences.com. This press release contains
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. Such statements involve
risks and uncertainties that could cause Hana's actual results to
differ materially from the anticipated results and expectations
expressed in these forward-looking statements. These statements are
based on current expectations, forecasts and assumptions that are
subject to risks and uncertainties, which could cause actual
outcomes and results to differ materially from these statements.
Among other things, there can be no assurances that any of Hana's
development efforts relating to its product candidates will be
successful. Other risks that may affect forward-looking information
contained in this press release include the possibility of being
unable to obtain regulatory approval of Hana's product candidates,
the risk that the results of clinical trials may not support Hana's
claims, Hana's reliance on third-party researchers to develop its
product candidates and its lack of experience in developing
pharmaceutical products. Additional risks are described in the
company's Annual Report on Form 10-KSB for the year ended Dec. 31,
2004. Hana assumes no obligation to update these forward-looking
statements, except as required by law.
Hana Biosciences (AMEX:HBX)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024
Hana Biosciences (AMEX:HBX)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024
Real-Time news about Hana Biosciences (American Stock Exchange): 0 recent articles
Plus d'articles sur Hana Biosciences Inc.